Study of Tumour Focused Radiotherapy for Bladder Cancer

Launched by INSTITUTE OF CANCER RESEARCH, UNITED KINGDOM · May 14, 2015

Keywords

ClinConnect Summary

The RAIDER trial is studying new ways to improve radiotherapy treatment for bladder cancer, specifically for patients with muscle-invasive bladder cancer. This type of cancer is serious and often requires strong treatments. In this trial, researchers are comparing three different approaches to radiotherapy: the standard treatment that targets the whole bladder, a method that focuses a stronger dose on the tumor, and an enhanced version of that tumor-focused method. The goal is to see if these new techniques can deliver higher doses of radiation directly to the tumor while keeping side effects manageable.

To participate in this trial, patients need to be at least 16 years old and have a specific type of bladder cancer that is localized and not spread to other areas. They must also be healthy enough to undergo radiotherapy and willing to follow up with regular hospital visits after their treatment. If someone joins the trial, they can expect to have multiple check-ups over the next two years to monitor their health and see how well the treatment works. Overall, the RAIDER trial hopes to provide important insights that could lead to better treatment options for bladder cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent
• • Age ≥16 years
• • Histologically or cytologically confirmed transitional cell carcinoma (TCC) of the bladder
• • Unifocal bladder TCC staged T2-T4a N0 M0\*
• • Fit to receive a radical course of radiotherapy
• • WHO performance status 0-2
• • Willing and able to comply with study procedures and follow up schedule \*Tumour location must be clearly visible on imagine or recorded on a surgical bladder map
• Exclusion Criteria:
• • Nodal or metastatic disease
• • Multifocal invasive disease
• • Simultaneous TCC in upper tract or urethra
• • Pregnancy
• • Active malignancy within 2 years of randomisation (not including non melanomatous skin carcinoma, previous non muscle invasive bladder tumours, NCCN low risk prostate cancer (T1/T2a, Gleason 6 PSA \<10), in situ carcinoma of any site)
• • Bilateral hip replacements
• • Any other conditions that in the Principal Investigator's opinion would be a contra-indication to radiotherapy (e.g. previous pelvic radiotherapy / inflammatory bowel disease)